7+Years of programmes
MultiMedical disciplines
GlobalSpeaker network
TrustedBy academia & industry
From fundamental research to industrial translation — GCGD 2027 invites original contributions across the full breadth of gastroenterology.
IBD therapeutics have entered a multi-mechanism era, with selective IL-23 inhibitors (risankizumab, mirikizumab), the S1P receptor modulator etrasimod, and the JAK1-selective upadacitinib joining established anti-TNFs and vedolizumab.
ExploreHepatology in 2027 is defined by the first FDA-approved MASH therapy — resmetirom (THR-beta agonist) following MAESTRO-NASH — and the rapid expansion of GLP-1 and dual agonists (semaglutide ESSENCE, survodutide, tirzepatide) into metabolic liver disease.
ExploreThird-space endoscopy has matured into a discipline of its own, with endoscopic submucosal dissection (ESD) increasingly preferred over EMR for high-risk early GI neoplasia and POEM established as a durable achalasia therapy.
ExploreGI oncology is being reshaped by molecularly stratified care: ctDNA-guided adjuvant decisions in stage II/III colon cancer (DYNAMIC, GALAXY), MSI-high tumors responding to neoadjuvant dostarlimab and pembrolizumab (with watch-and-wait emerging in rectal cancer), and HER2-positive gastric/GEJ disease driven by trastuzumab deruxtecan and zolbetuximab (CLDN18.
ExploreDisorders of gut-brain interaction are being reframed by Rome IV, high-resolution manometry, and the wireless motility capsule.
ExploreMicrobiota therapeutics have transitioned from investigational FMT into FDA-approved live biotherapeutic products: Rebyota (RBL-2660) and Vowst (SER-109) for prevention of recurrent C.
ExploreGCGD 2027 is a global forum for pioneering research, clinical translation and cross-disciplinary dialogue across gastroenterology and digestive diseases.
Across two days of keynotes, parallel technical tracks, video sessions and applied workshops, we convene the brightest minds to chart the frontier of GI care.
GCGD 2027 is more than a conference — it is a launchpad for your research, your clinical practice, and your next translational collaboration.
Hear first on breakthrough findings across 35 scientific sessions in gastroenterology.
Keynote, plenary and invited speakers from leading US and international institutions.
Connect with researchers, clinicians and industry leaders across 12+ countries — in one room, over two days.
All accepted abstracts published in the ISBN-allocated proceedings; selected papers invited to partner journals.
Best Paper, Best Poster and Young Investigator awards with global visibility and certificates of excellence.
Two days of curated networking and a gala dinner — attend on-site in the USA or stream every session live, worldwide.
Early-bird pricing available until July 14, 2026. All fees include the full two-day program, conference kit, lunches and networking events.
Mark these deadlines to stay ahead of abstract submission, registration and arrival.
Everything you need to submit abstracts, prepare presentations, and share GCGD 2027 with your colleagues.